Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008

BACKGROUND: Drug resistance of B-cell precursor acute lymphoblastic leukemia (BP-ALL) cells is conferred by both intrinsic and extrinsic factors, which could be targeted to promote chemo-sensitization. Our previous studies showed that Galectin-3, a lectin that clusters galactose-modified glycoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz, Helicia, Joo, Eun Ji, Chou, Chih-Hsing, Fei, Fei, Mayo, Kevin H., Abdel-Azim, Hisham, Ghazarian, Haike, Groffen, John, Heisterkamp, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870532/
https://www.ncbi.nlm.nih.gov/pubmed/29580262
http://dx.doi.org/10.1186/s13046-018-0721-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870532/
https://www.ncbi.nlm.nih.gov/pubmed/29580262
http://dx.doi.org/10.1186/s13046-018-0721-7

Ejemplares similares